Details for Patent: 8,450,287
✉ Email this page to a colleague
Which drugs does patent 8,450,287 protect, and when does it expire?
Patent 8,450,287 protects TOBRADEX ST and is included in one NDA.
Summary for Patent: 8,450,287
| Title: | Topical ophthalmic compositions containing tobramycin and dexamethasone |
| Abstract: | Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage. |
| Inventor(s): | Kabra; Bhagwati P. (Euless, TX) |
| Assignee: | Alcon Research, Ltd. (Fort Worth, TX) |
| Application Number: | 13/311,716 |
|
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 8,450,287
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | TOBRADEX ST | dexamethasone; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050818-001 | Feb 13, 2009 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
